Critical Review

You have full text access to this OnlineOpen article

Unraveling the mysteries of protein folding and misfolding

  1. Heath Ecroyd†,*,
  2. John A. Carver

Article first published online: 2 SEP 2008

DOI: 10.1002/iub.117

Issue

IUBMB Life

IUBMB Life

Volume 60, Issue 12, pages 769–774, December 2008

Additional Information

How to Cite

Ecroyd, H. and Carver, J. A. (2008), Unraveling the mysteries of protein folding and misfolding. IUBMB Life, 60: 769–774. doi: 10.1002/iub.117

Author Information

  1. School of Chemistry and Physics, University of Adelaide, Adelaide, SA, Australia

  1. †

    Tel: +61-8-8303-5505

*School of Chemistry & Physics, University of Adelaide, Adelaide, SA 5005. Australia

Publication History

  1. Issue published online: 20 NOV 2008
  2. Article first published online: 2 SEP 2008
  3. Manuscript Accepted: 5 JUN 2008
  4. Manuscript Received: 4 JUN 2008

Funded by

  • National Health and Medical Research Council (NHMRC) Peter Doherty Fellowship
  • NHMRC
  • Australian Research Council

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (205K)

REFERENCES

  • 1
    Anfinsen, C. B. ( 1973) Principles that govern the folding of protein chains. Science 181, 223–230.
  • 2
    Ellis, R. J. ( 2001) Macromolecular crowding: an important but neglected aspect of the intracellular environment. Curr. Opin. Struct. Biol. 11, 114–119.
  • 3
    Dobson, C. M. ( 2003) Protein folding and misfolding. Nature 426, 884–890.
  • 4
    Chiti, F., and Dobson, C. M. ( 2006) Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 75, 333–366.
  • 5
    Dobson, C. M. ( 2004) Experimental investigation of protein folding and misfolding. Methods 34, 4–14.
  • 6
    Stefani, M., and Dobson, C. M. ( 2003) Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J. Mol. Med. 81, 678–699.
  • 7
    Harper, J. D., and Lansbury, P. T.Jr. ( 1997) Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem. 66, 385–407.
  • 8
    Ecroyd, H.,Koudelka, T.,Thorn, D. C.,Williams, D. M.,Devlin, G.,Hoffmann, P., and Carver, J. A. ( 2008) Dissociation from the oligomeric state is the rate-limiting step in amyloid fibril formation by kappa-casein. J. Biol. Chem. 283, 9012–9022.
  • 9
    Jimenez, J. L.,Nettleton, E. J.,Bouchard, M.,Robinson, C. V.,Dobson, C. M., and Saibil, H. R. ( 2002) The protofilament structure of insulin amyloid fibrils. Proc. Natl. Acad. Sci. USA 99, 9196–9201.
  • 10
    Dobson, C. M. ( 2001) The structural basis of protein folding and its links with human disease. Philos. Trans. R. Soc. Lond. B Biol. Sci. 356, 133–145.
  • 11
    Dobson, C. M. ( 1999) Protein misfolding, evolution and disease. Trends Biochem. Sci. 24, 329–332.
  • 12
    Guijarro, J. I.,Sunde, M.,Jones, J. A.,Campbell, I. D., and Dobson, C. M. ( 1998) Amyloid fibril formation by an SH3 domain. Proc. Natl. Acad. Sci. USA 95, 4224–4228.
  • 13
    Fandrich, M.,Fletcher, M. A., and Dobson, C. M. ( 2001) Amyloid fibrils from muscle myoglobin. Nature 410, 165–166.
  • 14
    Chiti, F.,Webster, P.,Taddei, N.,Clark, A.,Stefani, M.,Ramponi, G., and Dobson, C. M. ( 1999) Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc. Natl. Acad. Sci. USA 96, 3590–3594.
  • 15
    Chiti, F.,Stefani, M.,Taddei, N.,Ramponi, G., and Dobson, C. M. ( 2003) Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature 424, 805–808.
  • 16
    DuBay, K. F.,Pawar, A. P.,Chiti, F.,Zurdo, J.,Dobson, C. M., and Vendruscolo, M. ( 2004) Prediction of the absolute aggregation rates of amyloidogenic polypeptide chains. J. Mol. Biol. 341, 1317–1326.
  • 17
    Fernandez-Escamilla, A. M.,Rousseau, F.,Schymkowitz, J., and Serrano, L. ( 2004) Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nat. Biotechnol. 22, 1302–1306.
  • 18
    Pawar, A. P.,Dubay, K. F.,Zurdo, J.,Chiti, F.,Vendruscolo, M., and Dobson, C. M. ( 2005) Prediction of “aggregation-prone” and “aggregation-susceptible” regions in proteins associated with neurodegenerative diseases. J. Mol. Biol. 350, 379–392.
  • 19
    Lopez de la Paz, M., and Serrano, L. ( 2004) Sequence determinants of amyloid fibril formation. Proc. Natl. Acad. Sci. USA 101, 87–92.
  • 20
    Bucciantini, M.,Giannoni, E.,Chiti, F.,Baroni, F.,Formigli, L.,Zurdo, J.,Taddei, N.,Ramponi, G.,Dobson, C. M., and Stefani, M. ( 2002) Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416, 507–511.
  • 21
    Novitskaya, V.,Bocharova, O. V.,Bronstein, I., and Baskakov, I. V. ( 2006) Amyloid fibrils of mammalian prion protein are highly toxic to cultured cells and primary neurons. J. Biol. Chem. 281, 13828–13836.
  • 22
    Ward, R. V.,Jennings, K. H.,Jepras, R.,Neville, W.,Owen, D. E.,Hawkins, J.,Christie, G.,Davis, J. B.,George, A.,Karran, E. H., and Howlett, D. R. ( 2000) Fractionation and characterization of oligomeric, protofibrillar and fibrillar forms of beta-amyloid peptide. Biochem. J. 348 Pt 1, 137–144.
  • 23
    Caughey, B., and Lansbury, P. T. ( 2003) Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 26, 267–298.
  • 24
    Lashuel, H. A., and Lansbury, P. T.,Jr. ( 2006) Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? Q. Rev. Biophys. 39, 167–201.
  • 25
    Tabner, B. J.,El-Agnaf, O. M.,German, M. J.,Fullwood, N. J., and Allsop, D. ( 2005) Protein aggregation, metals and oxidative stress in neurodegenerative diseases. Biochem. Soc. Trans. 33, 1082–1086.
  • 26
    Ono, K.,Hamaguchi, T.,Naiki, H., and Yamada, M. ( 2006) Anti-amyloidogenic effects of antioxidants: implications for the prevention and therapeutics of Alzheimer's disease. Biochim. Biophys. Acta 1762, 575–586.
  • 27
    Ehrnhoefer, D. E.,Bieschke, J.,Boeddrich, A.,Herbst, M.,Masino, L.,Lurz, R.,Engemann, S.,Pastore, A., and Wanker, E. E. ( 2008) EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat. Struct. Mol. Biol. 15, 558–566.
  • 28
    Carver, J. A.,Rekas, A.,Thorn, D. C., and Wilson, M. R. ( 2003) Small heat-shock proteins and clusterin: intra- and extracellular molecular chaperones with a common mechanism of action and function? IUBMB Life 55, 661–668.
    Direct Link:
  • 29
    Ecroyd, H.,Meehan, S.,Horwitz, J.,Aquilina, J. A.,Benesch, J. L.,Robinson, C. V.,Macphee, C. E., and Carver, J. A. ( 2007) Mimicking phosphorylation of alphaB-crystallin affects its chaperone activity. Biochem. J. 401, 129–141.
  • 30
    Rekas, A.,Adda, C. G.,Aquilina, J. A.,Barnham, K. J.,Sunde, M.,Galatis, D.,Williamson, N. A.,Masters, C. L.,Anders, R. F.,Robinson, C. V.,Cappai, R., and Carver, J. A. ( 2004) Interaction of the molecular chaperone alphaB-crystallin with alpha-synuclein: effects on amyloid fibril formation and chaperone activity. J. Mol. Biol. 340, 1167–1183.
  • 31
    Hatters, D. M.,Lindner, R. A.,Carver, J. A., and Howlett, G. J. ( 2001) The molecular chaperone, alpha-crystallin, inhibits amyloid formation by apolipoprotein C-II. J. Biol. Chem. 276, 33755–33761.
  • 32
    Sun, Y., and MacRae, T. H. ( 2005) The small heat shock proteins and their role in human disease. FEBS J. 272, 2613–2627.
    Direct Link:
View Full Article (HTML) Get PDF (205K)